Drawing for ACINO PHARMA - DELIVERING HEALTH

USPTO serial 79130005

ACINO PHARMA - DELIVERING HEALTH

Reviewed by CopyMark Law Group

Reg. 4479450Status 404
Filing date
Status date
Registration date
Feb 11, 2014
Examiner
GILLES, DEBORAH LYNN MEINERS
Law office
PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with ACINO PHARMA - DELIVERING HEALTH?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

William J. Seiter

William J. Seiter Seiter Legal Studio2500 Broadway, Bldg F, Suite F-125Santa Monica, CA 90404UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceuticals for treating pain, infectious diseases, namely, respiratory infections, gastroenterological system infections, infections of the genitourinary system, infections of the mouth and teeth, namely, tooth abscess, eye infections, ear infections; pharmaceuticals for treating viral diseases, namely, herpes, hepatitis, acquired immune deficiency syndrome (AIDS); pharmaceuticals for treating neurological diseases, namely, Alzheimer's disease, Huntington's disease, cerebral palsy, encephalitis, epilepsy, migraine, insomnia; pharmaceuticals for treating the central nervous system, namely, infections of the central nervous system, brain diseases, motor disorders, diseases of the spinal cord; pharmaceuticals for treating psychiatric diseases, namely, mood disorders, anxiety disorders, cognitive disorders, psychotic disorders; pharmaceuticals for use in oncology; pharmaceuticals for the treatment of cardiovascular diseases; pharmaceuticals for treating the respiratory system; pharmaceuticals for use in gastroenterology; pharmaceuticals for treating oral and dental diseases, namely, oral vaccine preparations; pharmaceutical preparations for use in ophthalmology; pharmaceuticals for treating inflammatory diseases, namely, inflammatory intestinal diseases, inflammatory diseases of the connective tissue; pharmaceuticals for treating immunological diseases, namely, autoimmune diseases, immune deficiency syndromes; pharmaceuticals for use in dermatology, namely, for treating dermatitis, skin pigmentation anomalies, sexually transmitted diseases; pharmaceuticals for treating the musculoskeletal system, namely, connective tissue diseases, bone diseases, diseases of the spinal column, back pain, fractures, sprains, cartilage lesions; dietetic substances for medical use, namely, nucleic acids, proteins, toxins, antibiotics, antiviral molecules, immunomodulators; plasters, materials for dressings for medical purposes; material for dental fillings and dental impressions; disinfectants, namely, all-purpose disinfectants, disinfectants for medical instruments and hand disinfectants for hygienic purposesSECTION 71 - CANCELLED—
042Scientific and technological services, namely, research services in the field of pharmacy, medicine and chemistry; scientific research consultancy, in particular in the field of pharmacy, medicine and chemistry; scientific consultancy in the field of pharmacologySECTION 71 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 2, 2023DENCNOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED—
Oct 2, 2023DETHDEATH OF INTERNATIONAL REGISTRATION—
Mar 13, 2022INNTTOTAL INVALIDATION PROCESSED BY THE IB—
Feb 17, 2022INTSTOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB—
Feb 17, 2022INPCINVALIDATION PROCESSED—
Oct 26, 2021INTRTOTAL INVALIDATION OF REG EXT PROTECTION CREATED—
Feb 26, 2021C71TCANCELLED SECTION 71—
Feb 11, 2019REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Mar 16, 2017TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Jun 9, 2016ADCHCHANGE OF NAME/ADDRESS REC'D FROM IB—
Jul 8, 2015ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jul 8, 2015REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jul 24, 2014FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Jun 20, 2014FICSFINAL DISPOSITION NOTICE SENT TO IB—
Jun 20, 2014FIMPFINAL DISPOSITION PROCESSED—
May 11, 2014FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Feb 11, 2014R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Dec 3, 2013GPNXNOTIFICATION PROCESSED BY IB—
Nov 26, 2013NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Nov 26, 2013PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Nov 13, 2013OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Nov 13, 2013OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Nov 6, 2013NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Oct 23, 2013PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Oct 20, 2013CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Oct 20, 2013XAECEXAMINER'S AMENDMENT ENTERED—
Oct 20, 2013GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Oct 20, 2013GNEAEXAMINERS AMENDMENT E-MAILED—
Oct 20, 2013CNEAEXAMINERS AMENDMENT -WRITTEN—
Oct 11, 2013TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Oct 11, 2013CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Oct 7, 2013ALIEASSIGNED TO LIE—
Oct 5, 2013ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
Sep 27, 2013GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
Sep 27, 2013GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Sep 27, 2013CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Sep 13, 2013CHLDCHANGE OF OWNER RECEIVED FROM IB—
Sep 9, 2013TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Sep 8, 2013CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 8, 2013TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jul 22, 2013RFNTREFUSAL PROCESSED BY IB—
Jun 28, 2013RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Jun 28, 2013RFRRREFUSAL PROCESSED BY MPU—
Jun 25, 2013RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Jun 24, 2013CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 17, 2013DOCKASSIGNED TO EXAMINER—
Jun 7, 2013MAFRAPPLICATION FILING RECEIPT MAILED—
Jun 3, 2013NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
May 31, 2013LIMILIMITATION FROM ORIGINAL APPLICATION ENTERED—
May 30, 2013REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance